Page last updated: 2024-08-17

prednisone and 1,2-dipalmitoyl-3-phosphatidylethanolamine

prednisone has been researched along with 1,2-dipalmitoyl-3-phosphatidylethanolamine in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Brandes, LJ; Klapp, K; Lieskovsky, G; Quinn, DI; Raghavan, D; Ramsey, EW; Snyder, T; Styles, E; Tsao-Wei, D	1

Trials

1 trial(s) available for prednisone and 1,2-dipalmitoyl-3-phosphatidylethanolamine

Article	Year
Phase II trial of tesmilifene plus mitoxantrone and prednisone for hormone refractory prostate cancer: high subjective and objective response in patients with symptomatic metastases. The Journal of urology, 2005, Volume: 174, Issue:5 Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Male; Maximum Tolerated Dose; Middle Aged; Mitoxantrone; Neoplasm Staging; Phosphatidylethanolamines; Prednisone; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Analysis; Treatment Outcome	2005

Article

Year

Phase II trial of tesmilifene plus mitoxantrone and prednisone for hormone refractory prostate cancer: high subjective and objective response in patients with symptomatic metastases.

The Journal of urology, 2005, Volume: 174, Issue:5

Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Male; Maximum Tolerated Dose; Middle Aged; Mitoxantrone; Neoplasm Staging; Phosphatidylethanolamines; Prednisone; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Analysis; Treatment Outcome

2005